ArticleMedChemComm2019
Derivatisation of parthenolide to address chemoresistant chronic lymphocytic leukaemia.
Abstract read
In one paragraph
Article in MedChemComm, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Structural Modification of Sesquiterpene Lactones via Michael Addition: Improved Bioactivity and Pharmacokinetics.International journal of molecular sciences · 2026Review
- Mutant ribosomal protein RPS15 drives B cell malignancy through oxidative stress and genomic instability.Nature communications · 2026Article
- A pathway to next-generation mast cell stabilizers identified through the novel Phytomedical Analytics for Research Optimization at scale data platform.Frontiers in pharmacology · 2026Article
- A pathway to next-generation mast cell stabilizers identified through the novel Phytomedical Analytics for Research Optimization at Scale data platform.bioRxiv : the preprint server for biology · 2025Article
- Synthesis and Antimicrobial Evaluation of (+)-Neoisopulegol-Based Amino and Thiol Adducts.International journal of molecular sciences · 2025Article
- Natural sesquiterpene lactones in prostate cancer therapy: mechanisms and sources.Medical oncology (Northwood, London, England) · 2025Review
- Parthenolide: pioneering new frontiers in hematological malignancies.Frontiers in pharmacology · 2025Review
- Synthesis and Anti-Inflammatory Activity of Ferulic Acid-Sesquiterpene Lactone Hybrids.Molecules (Basel, Switzerland) · 2024Article
- Article
- Regioselective and Stereoselective Synthesis of Parthenolide Analogs by Acyl Nitroso-Ene Reaction and Their Biological Evaluation againstInternational journal of molecular sciences · 2023Article
- Parthenolide Induces ROS-Mediated Apoptosis in Lymphoid Malignancies.International journal of molecular sciences · 2023Article
- An Overview of NRF2-Activating Compounds Bearing α,β-Unsaturated Moiety and Their Antioxidant Effects.International journal of molecular sciences · 2022Review
- Computational detection of a genome instability-derived lncRNA signature for predicting the clinical outcome of lung adenocarcinoma.Cancer medicine · 2022Article
- Sesquiterpene Lactones: Promising Natural Compounds to Fight Inflammation.Pharmaceutics · 2021Review
- Electrophilic reactivities of cyclic enones and α,β-unsaturated lactones.Chemical science · 2021Article
- Aniline-containing derivatives of parthenolide: Synthesis and anti-chronic lymphocytic leukaemia activity.Tetrahedron · 2020Article
- Derivatisation of parthenolide to address chemoresistant chronic lymphocytic leukaemia.MedChemComm · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Xingjian LiSchool of Chemistry, University of Birmingham, Edgbaston, Birmingham, West Midlands B15 2TT, UK. Email: j.s.fossey@bham.ac.uk.ORCID 0000-0001-9842-786X
Daniel T PayneSchool of Chemistry, University of Birmingham, Edgbaston, Birmingham, West Midlands B15 2TT, UK. Email: j.s.fossey@bham.ac.uk.ORCID 0000-0001-7707-8381
Badarinath AmpoluSygnature Discovery, The Discovery Building, BioCity, Pennyfoot Street, Nottingham, NG1 1GR, UK.
Nicholas BlandSygnature Discovery, The Discovery Building, BioCity, Pennyfoot Street, Nottingham, NG1 1GR, UK.
Jane T BrownSygnature Discovery, The Discovery Building, BioCity, Pennyfoot Street, Nottingham, NG1 1GR, UK.
Mark J DuttonSchool of Chemistry, University of Birmingham, Edgbaston, Birmingham, West Midlands B15 2TT, UK. Email: j.s.fossey@bham.ac.uk.
Catherine A FittonInstitute for Cancer and Genomic Sciences, University of Birmingham, Edgbaston, Birmingham, West Midlands B15 2TT, UK. Email: a.agathanggelou@bham.ac.uk.ORCID 0000-0001-6403-1314
Abigail GulliverWinterbourne Botanic Garden, University of Birmingham, 58 Edgbaston Park Road, Edgbaston, Birmingham, West Midlands B15 2RT, UK.
Lee HaleWinterbourne Botanic Garden, University of Birmingham, 58 Edgbaston Park Road, Edgbaston, Birmingham, West Midlands B15 2RT, UK.
Daniel HamzaSygnature Discovery, The Discovery Building, BioCity, Pennyfoot Street, Nottingham, NG1 1GR, UK.
Geraint JonesSygnature Discovery, The Discovery Building, BioCity, Pennyfoot Street, Nottingham, NG1 1GR, UK.
Rebecca LaneSygnature Discovery, The Discovery Building, BioCity, Pennyfoot Street, Nottingham, NG1 1GR, UK.
Andrew G LeachSchool of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Byrom Street, Liverpool, L3 3AF, UK.ORCID 0000-0003-1325-8273
Louise MaleX-Ray Crystallography Facility, School of Chemistry, University of Birmingham, Edgbaston, Birmingham, West Midlands B15 2TT, UK.
Elena G MerisorSygnature Discovery, The Discovery Building, BioCity, Pennyfoot Street, Nottingham, NG1 1GR, UK.
Michael J MortonApconiX Ltd, Alderly Park, Nether Alderly, Cheshire, SK10 4TG, UK.ORCID 0000-0002-7443-8828
Alex S QuySchool of Chemistry, University of Birmingham, Edgbaston, Birmingham, West Midlands B15 2TT, UK. Email: j.s.fossey@bham.ac.uk.ORCID 0000-0002-4507-0796
Ruth RobertsApconiX Ltd, Alderly Park, Nether Alderly, Cheshire, SK10 4TG, UK.ORCID 0000-0002-7763-7558
Rosanna ScarllInstitute for Cancer and Genomic Sciences, University of Birmingham, Edgbaston, Birmingham, West Midlands B15 2TT, UK. Email: a.agathanggelou@bham.ac.uk.
Timothy Schulz-UtermoehlSygnature Discovery, The Discovery Building, BioCity, Pennyfoot Street, Nottingham, NG1 1GR, UK.
Tatjana StankovicInstitute for Cancer and Genomic Sciences, University of Birmingham, Edgbaston, Birmingham, West Midlands B15 2TT, UK. Email: a.agathanggelou@bham.ac.uk.
Brett StevensonSygnature Discovery, The Discovery Building, BioCity, Pennyfoot Street, Nottingham, NG1 1GR, UK.
John S FosseySchool of Chemistry, University of Birmingham, Edgbaston, Birmingham, West Midlands B15 2TT, UK. Email: j.s.fossey@bham.ac.uk.ORCID 0000-0002-2626-5117
Angelo AgathanggelouInstitute for Cancer and Genomic Sciences, University of Birmingham, Edgbaston, Birmingham, West Midlands B15 2TT, UK. Email: a.agathanggelou@bham.ac.uk.ORCID 0000-0001-9529-2111
Funding
Medical Research Council MC_PC_14107Medical Research Council MC_PC_17183
Abstract
Parthenolide is a natural product that exhibits anti-leukaemic activity, however, its clinical use is limited by its poor bioavailability. It may be extracted from
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.